In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Tenaya Therapeutics, with a price target of $3.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors that highlight Tenaya Therapeutics’ promising advancements in their clinical programs. The company has made significant progress in normalizing cardiac protein expression, which is crucial for the success of their gene therapy treatments for MYBPC3-HCM and PKP2-ARVC. By utilizing innovative quantification methods, Tenaya is able to achieve more accurate and consistent results, which could lead to better therapeutic outcomes.
Furthermore, the upcoming data readouts in Q4 2025 for their TN-201 and TN-401 programs are anticipated to provide further insights into the efficacy of their treatments. The expectation of continued improvements or stabilization in biomarkers, along with additional biopsy data, supports a positive outlook for the company’s future performance. These factors, combined with a strategic approach to addressing inter- and intra-patient variability, underpin the Buy rating given by Cory Jubinville, PhD.
In another report released on August 27, H.C. Wainwright also maintained a Buy rating on the stock with a $5.00 price target.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TNYA in relation to earlier this year.